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2262Dual antiplatelet therapy with
aspirin and a P2Y12 receptor
blocker to inhibit platelet reactivity
(PR) and toprevent ischemic event
occurrences is an effective phar-
macologic therapy administered
to patients with acute coronary
syndromes (ACS) or those un-
dergoing percutaneous coronary
intervention (PCI) (1–3). Except
for recommendations related to
some speciﬁc demographic vari-
ables, for example, the history of
transient ischemic attack or stroke
that precludes prasugrel use in
ACS undergoing PCI, a “one-
size-ﬁts-all” approach for P2Y12
receptor blockers is mostly em-
ployed based on clinical trial
results. However, the pharmaco-
dynamic effect of clopidogrel has
been shown to be widely variable,
whereas prasugrel and ticagrelor
are associated with a more uni-
form antiplatelet response (4–10).
In the past decade, compelling
evidence from numerous observa-
tional studies has emerged dem-
onstrating a strong association
between high platelet reactivity
to adenosine diphosphate (HPR)
and post-PCI ischemic events,
especially stent thrombosis (ST)
(4). Earlier, we provided a con-
sensus opinion on the deﬁnition
ofHPRbased on variousmethodsternal Medicine, Rehabilitation, and Geriatrics,
niversity Hospitals and School of Medicine,
ts-Herzzentrum Freiburg-Bad Krozingen, Bad
epartment of Cardiology, Ludwig-Maximilians
Klinik und Poliklinik I, Munich, Germany.
lectures and travel support from Accumetrics.
onsulting fees from sanoﬁ-aventis, AstraZeneca,
istance Publique Hopitaux de Marseille and
consulting fees from Verum Diagnostica; and
, Roche, DSI/Lilly, AstraZeneca, Pﬁzer, Bayer
s received speaking fees from AstraZeneca and
g fees from AstraZeneca, Daiichi Sankyo/Lilly
umetrics, The Medicines Company, Merck &
, Bristol-Myers Squibb/sanoﬁ-aventis, Terumo,
rest in Iverson Genetics. Dr. Jeong has received
entis, Daiichi Sankyo/Lilly, Nanosphere, Hae-
ants or support from Dong-A Pharmaceuticals,
Ingelheim, Otsuka, Accumetrics, and Haemo-
nsulting fees or honoraria from Bristol-Myers
ichi Sankyo, The Medicines Company, Astra-
bbott Vascular, and PLx Pharma; payment for
Johnson & Johnson, St. Jude Medical, and
rants from Bristol-Myers Squibb, sanoﬁ-aventis,
, Daiichi Sankyo, The Medicines Company,reported in the literature (4). Since then, updated American
College of Cardiology Foundation/American Heart Asso-
ciation/Society for Cardiovascular Angiography and Inter-
ventions and European Society of Cardiology guidelines
issued a Class IIb recommendation for platelet function
testing (PFT) to facilitate the choice of P2Y12 inhibitor in
selected, high-risk patients undergoing PCI, although
routine PFT is not recommended (Class III, no beneﬁt)
(Online Appendix, Box-1) (1–3). Recent prospective ran-
domized trials evaluating personalized antiplatelet therapy
based on PFT did not demonstrate clinical beneﬁt, thus
questioning whether treatment modiﬁcation based on the
results of PFT can actually inﬂuence outcomes (11–13). It
should be acknowledged that these randomized trials are
associated with major limitations. There are also contro-
versies regarding the low positive predictive value of PFT,
which some investigators have proposed has limitations in its
clinical utility for individual patients. However, others have
argued that an application of diagnostic test statistics is not
appropriate for a prognostic test such as PFT (14–16). In
this updated consensus document, we aim to review the
available evidence addressing the relation of PR to throm-
botic and bleeding events. We propose updated cutoff values
for HPR and low platelet reactivity to adenosine diphos-
phate (LPR) that might be used in future investigations of
personalized antiplatelet therapy. Finally, we highlight the
major limitations of the randomized trials that failed to
demonstrate the utility of PFT.
Many of the earlier studies that attempted to link ex vivo
evidence of heightened PR to ischemic events were criticized
for the potential introduction of artifacts by the laboratory
methods. The ﬁndings were regarded as “unconvincing”
because the PFT were thought to be poor substitutes for the
complex interactions taking place in vivo (17). Correlations
between various assays were not robust; moreover, there
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2263with and without ischemic events (18,19). A large number of
recent observational studies involving more than 20,000
patients demonstrated that HPR during clopidogrel treat-
ment is a strong and independent risk factor for post-PCI
thrombotic events (20–23). In addition, the most widely
used assays (VerifyNow P2Y12 assay [Accumetrics, San
Diego, California], Multiplate Analyzer [F. Hoffmann-La
Roche Ltd., Basel, Switzerland], vasodilator-stimulated
phosphoprotein-phosphorylation [VASP-P] assay [Diag-
nostica Stago, Biocytex, Asnières, France]) have overcome
many of the technical and methodological limitations of
previous assays, including conventional light transmittance
aggregometry.
Platelet Function Measurement
in Patients Undergoing PCI
Recently, the multinational prospective registry study
ADAPT-DES (Assessment of Dual AntiPlatelet Therapy
with Drug-Eluting Stents) (w50% of patients with ACS)
reinforced the independent association between HPR and
deﬁnite/probable ST (16). In this study, HPR (>208 P2Y12
reaction units [PRU]) was independently associated with an
w3-fold increased risk for 30-day deﬁnite/probable ST
(propensity-adjusted hazard ratio [HR]: 3.00, 95% conﬁ-
dence interval [CI]: 1.39 to 6.49; p ¼ 0.005). Furthermore,
>208 PRU remained an independent predictor of 1-year
deﬁnite/probable ST (adjusted HR: 2.49, 95% CI: 1.43 to
4.31; p ¼ 0.001) and myocardial infarction (MI) (adjusted
HR: 1.42, 95% CI: 1.09 to 1.86; p ¼ 0.01). Although
signiﬁcantly more patients with HPR had died at 1-year
follow-up, HPR was not an independent predictor of
mortality after adjusting for a large number of confounding
variables (HR: 1.20, 95% CI: 0.85 to 1.70; p ¼ 0.30). The
authors observed that HPR had a greater impact in ACS
patients than in stable coronary artery disease (CAD)
patients (16).
The importance of HPR and treatment with intensiﬁed
therapy should be interpreted in the context of patient
characteristics such as ethnicity and underlying risk. In
a study of 1,220 East Asian patients, HPR (>272 PRU) was
associated with cardiovascular events at 1-year follow-upCardiology Today Intervention), WebMD (continuing medical education steering
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from Boehringer Ingelheim, Daiichi Sankyo, and Eli Lilly; lecture fees fromamong acute MI patients, whereas there was no relation in
those without acute MI (24). Similarly, Park et al. (25)
demonstrated that HPR >235 PRU was independently
associated with the primary composite endpoint of death,
MI, ST, or stroke in East Asian patients undergoing PCI
with ACS, but not with stable CAD patients.
There is further support for an association between
HPR determined ex vivo and coronary atherosclerosis and
thrombotic event occurrence in vivo. HPR (>230 PRU)
during clopidogrel therapy was independently associated
with greater coronary artery atherosclerotic burden and
plaque calciﬁcation as measured by intravascular ultrasound
imaging (26). An association between PR and systemic
inﬂammation/procoagulant marker elevation has also been
described in patients with CAD (27–29). In addition to the
extensive literature on HPR in clopidogrel-treated patients,
recent observational studies suggest that HPR is also rele-
vant to the new P2Y12 receptor blockers (6,9,10).
In summary, the evidence that supports the potential
utility of PFT as a prognostic marker among patients
undergoing PCI includes: 1) the accepted highly platelet-
related pathophysiology of atherothrombosis and its
clinical phenotypes; 2) the consistent conﬁrmation of an
association between HPR and ischemic event occurrence; 3)
the results of randomized clinical trials demonstrating lower
thrombotic event rates in patients treated with pharmaco-
dynamically more potent agents than clopidogrel; and 4)
lack of difference in the ﬁnal mechanism of action between
P2Y12 receptor blockers. From a statistical perspective, PFT
fulﬁlls several criteria as a robust prognostic marker. In
particular, HPR is associated with substantial hazard for
thrombotic events (11) and improves net reclassiﬁcation
for major adverse clinical events (16,21).
Platelet Function Measurement in
Medically-Managed Patients
Although prognostic utility of HPR is robust in patients
undergoing PCI, its clinical relevance in medically-managed
ACS patients or in stable CAD patients is less clear. In
a recent study, antiplatelet drug responsiveness assessed by
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2264over common risk factors for the occurrence of major adverse
cardiovascular events at 3-year follow-up in stable patients
(n ¼ 771) with symptomatic atherothrombotic disease
managed medically with aspirin and/or clopidogrel (30).
In the TRILOGY-ACS (Targeted Platelet Inhibition to
Clarify the Optimal Strategy to Medically Manage Acute
Coronary Syndromes) platelet function substudy (n¼ 2,564),
the greater platelet inhibition provided by prasugrel versus
clopidogrel did not translate into an improved event-free
survival in the overall study (7). In an unadjusted analysis,
HPR (PRU >208) was associated with the occurrence of the
primary composite endpoint (cardiovascular death, MI, or
stroke) through 30 months. However, in an adjusted analysis
including a large number of demographic and clinical char-
acteristics, HPR did not remain an independent predictor of
adverse events (7). Some limitations merit discussion
regarding the TRILOGY study. Patients were not-
randomized and platelet function was not measured during
the initial period of potentially highest thrombotic risk
(patients were enrolled and randomized 4 to 10 days after the
index event). The TRILOGY study enrolled a signiﬁcant
proportion of patients who did not have proven evidence of
signiﬁcant CAD in whom PR to adenosine diphosphate
(ADP) may not have inﬂuenced outcome. Finally, the
adjusted analysis included multiple risk factors and covariates
that may inﬂuence thrombotic outcomes by their effect on
platelet physiology and thereby could have masked the inde-
pendent association of HPR on ischemic events. Although
multivariable adjustment is important to suggest causal rela-
tionships between risk factors and events, univariate associa-
tions may be more important for the treating physician who is
unable to adjust test results for multiple variables at the
bedside. Indeed, HPR has been associated with several
prognostic variables including ACS, diabetes, high body
weight, older age, reduced left ventricular ejection fraction, or
elevated C-reactive protein (31,32), whereas smoking has
been associated with a lower frequency of HPR in some
studies (33,34).
Treatment intervention based on platelet function mea-
surement was used to reduce post-PCI thrombotic events in
the GRAVITAS (Gauging Responsiveness With a Ver-
ifyNow Assay–Impact on Thrombosis and Safety) trial. PCI
patients with HPR (235 PRU) were randomly assigned to
either standard dose clopidogrel or a repeated 600-mg
loading dose of clopidogrel followed by 150 mg daily (high
dose). High-dose clopidogrel treatment was ineffective in
reducing the 6-month composite ischemic event occurrence
of cardiovascular death, nonfatal MI, and ST. Notably, the
event rate was low (2.3% vs. 5% used for power calculation);
therefore, the study was substantially underpowered (11). In
addition to being underpowered, there are other potential
explanations for the neutral results of GRAVITAS trial (35).
In a time-dependent analysis of GRAVITAS, <208 PRU
was independently associated with the 60-day primary
endpoint (HR: 0.23, 95% CI: 0.05 to 0.98; p ¼ 0.047) and
tended to be an independent predictor at 6 months (HR:0.54, 95%CI: 0.28 to 1.04; p¼ 0.06) (36). Only a minority of
patients receiving high-dose clopidogrel achieved <208
PRU, indicating that the high-dose clopidogrel regimen may
have been suboptimal. A more potent intervention that
reduces HPR to a greater extent would have had greater
potential to improve clinical outcomes given the very low
event rate. In support of this hypothesis, the ELEVATE–
TIMI 56 (Escalating Clopidogrel by Involving a Genetic
Strategy–Thrombolysis In Myocardial Infarction 56) trial
showed that up to 225 mg of clopidogrel might be necessary
to overcome HPR in patients carrying 1 loss-of-function
cytochrome 2C19 gene (37). The GRAVITAS trial
enrolled a population at low absolute risk for ischemic events
despite displaying HPR. The majority of patients had stable
angina and were successfully treated with PCI, and peri-
procedural events were not included in the primary endpoint.
The tested pharmacologic intervention was administered
more than 12 h after PCI, and the associated acute vessel
injury/stent deployment, which may have been too late to
blunt a platelet-related incipient lesion. Finally, it is possible
that a single PFT will not reliably reﬂect the effect of clopi-
dogrel on ADP-induced PR in all patients (35).
In the ARCTIC (Assessment by a Double Randomiza-
tion of a Conventional Antiplatelet Strategy Versus a
Monitoring-Guided Strategy for Drug-Eluting Stent Im-
plantation and of Treatment Interruption Versus Continu-
ation One Year After Stenting) study, 2,440 patients were
randomly assigned to either a strategy of platelet function
monitoring and drug adjustment or to a conventional
strategy without platelet function monitoring according to
the clinicians’ preference (13). The 1-year primary com-
posite endpoint of death, MI, ST, stroke, or urgent revas-
cularization was similar in both arms (34.6% vs. 31.1%;
HR: 1.13, 95% CI: 0.98 to 1.29; p ¼ 0.10), mostly driven
by periprocedural MI that was assessed by nonstandard
methodology (single troponin assessment 6 h after the
procedure). However, protocol implementation was incom-
plete: 73% of patients with HPR received an additional
clopidogrel loading dose, whereas only 4% received a prasu-
grel loading dose. Similar to the GRAVITAS trial, the
primary intervention in the maintenance phase among
patients with HPR was clopidogrel 150 mg, 15.6% of the
patients in the monitoring group had HPR at 2- to 4-week
follow-up despite monitoring, and the study population was
at low absolute risk for cardiovascular events. Importantly,
twice as many patients were lost to follow-up in the
conventional than in the monitoring arm (3.8% vs. 1.9%).
Finally, the composite endpoint in this study also included
other events, such as death from any cause, that may not be
related to platelet function (13).
The TRIGGER-PCI (Testing Platelet Reactivity in
Patients Undergoing Elective Stent Placement on Clopi-
dogrel to Guide Alternative Therapy With Prasugrel) study
is the only trial using a potentially effective strategy to
overcome HPR. Stable angina patients with >208 PRU
were randomized after successful drug-eluting stent PCI
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2265to prasugrel or standard-dose clopidogrel. However, the
study was terminated prematurely after a non–pre-speciﬁed
interim analysis due to a largely lower rate of ischemic
events than anticipated that precluded the establishment of
meaningful results. Approximately 30% of the enrolled
patients declined randomization after being identiﬁed as
having HPR, which is suggestive of selection bias. The very
low event rates in patients with stable CAD successfully
treated with current drug-eluting stent, even among those
hyporesponsive to clopidogrel, suggest that this patient
population will be challenging for future studies to
demonstrate the beneﬁts of PFT-directed therapies (12).
Although the results of the latter 3 randomized trials were
negative, smaller studies have suggested that the PFT-
directed approach may be effective depending on the
method of implementation. Two small multicenter trials
employed the VASP-P assay to tailor incremental loading
doses of clopidogrel to reduce on-treatment PR below the
HPR cutoff. This strategy was associated with signiﬁcantly
reduced subsequent adverse event occurrence, including
early ST without increasing bleeding (38,39). Similarly, 2
other studies have suggested that the selective admini-
stration of a glycoprotein IIb/IIIa receptor inhibitor to
patients undergoing elective PCI who were identiﬁed as
poor responders to aspirin or clopidogrel was effective in
reducing both 30-day and 1-year ischemic events without
increased bleeding rates (40,41). In addition, the non-
randomized MADONNA (Multiple Electrode Aggregom-
etry in Patients Receiving Dual Antiplatelet Therapy to
Guide Treatment With Novel Platelet Antagonists) study
(n ¼ 798) (42) and a randomized study by Hazarbasanov
et al. (43) suggested that an individualized antiplatelet
regimen based on PFT measured by a Multiplate analyzer
can reduce post-PCI ischemic event occurrences without an
increase in bleeding risk. Of importance, all of these studies
aimed to decrease PR below the threshold of HPR, which is
associated with post-PCI ischemic events.
Finally, a meta-analysis of 9 randomized trials compared
intensiﬁed antiplatelet therapy with standard therapy in
patients with HPR (20). Although the analysis included
some small-sized trials, and the strategy to intensify platelet
inhibition was heterogeneous, the results showed a signiﬁ-
cant reduction in cardiovascular mortality and ST in HPR
patients when intensiﬁed antiplatelet therapy was used.
Of interest, the beneﬁt was mostly observed in high-risk
patients, suggesting that other factors, including demo-
graphic, clinical, and angiographic factors, must be also
taken into consideration to optimally identify the patients at
greatest risk. Along this line, recent studies have suggested
that adding clinical variables and genotype to PFT may
improve risk prediction (31,32).
PR and Bleeding
During the era of dual antiplatelet therapy with aspirin
and ticlopidine/clopidogrel, the evaluation of antiplatelettherapies has been largely focused on reducing ischemic
event occurrence (efﬁcacy). Bleeding (safety) was often
considered as an inevitable and acceptable complication.
However, in the era of more potent P2Y12 receptor inhibi-
tors, there is a heightened risk for bleeding. The balance
between the absolute risk reduction in ischemic events and
the absolute risk increase in bleeding events (particularly
assessed by more sensitive bleeding scales) with more potent
agents remains delicate. A therapeutic counterpoise may
occur, with the absolute risk reduction in ischemic event
occurrence and the absolute risk increase in bleedings
approaching to the same magnitude (44). Current knowl-
edge suggests that there may be a “ceiling effect” in reducing
ischemic event occurrence even with new P2Y12 receptor
inhibitors (i.e., 10% residual ischemic event occurrence).
Furthermore, in the contemporary registries and trials of
PCI, the absolute rate of ischemic events at 1-year follow-up
is low (16,32). Given this scenario, the focus is now shifting
toward ﬁnding strategies that could avoid excessive bleeding
while maintaining the beneﬁt of reduced ischemic/throm-
botic events (45). This paradigm evolution also led to the
introduction of novel clinical endpoints such as the “net
adverse clinical events” in ongoing and future trials. It could
be argued that more potent antiplatelet therapies may be
optimal when the beneﬁt of reducing ischemic events
outweighs the risk of bleeding. Accordingly, the greater net
clinical beneﬁt of the more potent P2Y12 blockade may be
observed early after stenting when thrombotic risk is the
highest (46).
Bleeding events have been associated with an increased
risk of short- and long-term morbidity and mortality in
CAD patients during long-term antiplatelet therapy and
anticoagulant therapy (47). In addition, the results of
randomized trials of anticoagulants suggest that a survival
beneﬁt might be attributable to reduction in bleeding alone
(48,49). Several potential reasons for the higher risk of
mortality associated with bleeding include: 1) premature
termination of obligatory therapies including antiplatelet
agents; 2) immunosuppression and platelet activation by
blood transfusion; and 3) hemodynamic compromise asso-
ciated with bleeding and greater prevalence of comorbidities
in patients who suffer from bleeding events (50). In addi-
tion, inﬂammatory, procoagulant, and other mechanisms
have been suggested as mediating factors for risk associated
with bleeding and transfusion (51). Finally, even superﬁcial
or “nuisance” bleeding may be clinically important as these
events are associated with premature drug discontinuation,
which may have an impact on clinical outcomes (52).
Challenges in Studying Bleeding Complications
A consensus has been reached regarding the deﬁnition of
ischemic events such as MI and ST (53,54). Although these
ischemic events are highly platelet-dependent, the underlying
mechanisms of bleeding are more complex and hetero-
geneous in origin. For example, the etiologies of
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2266gastrointestinal, intracranial, surgical, and nuisance bleedings
are distinct. The role that platelet function plays in these
different types of bleeding might vary, and it might be related
to the extent of impaired hemostatic potential and possibly
a higher degree of platelet inhibition. Moreover, variable
transfusion triggers and perioperatively relevant covariates
have to be considered in surgery-related bleeding (55).
Compared with the composite endpoint of cardiovascular
death, MI, or stroke, the prevalence of “major” or “severe”
bleeding is generally low; therefore, it is more difﬁcult to
study mechanisms of major bleeding as compared to ischemic
event outcomes due to the large number of patients required.
Moreover, characteristics such as older age, chronic kidney
disease, female sex, and diabetes share heightened risk for
both bleeding and ischemic events (56). Previous randomized
clinical trials used various bleeding deﬁnitions, and this has
produced a library of heterogeneous classiﬁcations for inci-
dence and severity. These diverse deﬁnitions have limited
comparisons of bleeding across trials (57). The Bleeding
Academic Research Consortium proposed a standardized
deﬁnition to better quantify bleeding events and to evaluate
new strategies to reduce the risk of bleeding in future
trials (48).
Relation of Platelet Function to Bleeding in
PCI-Treated Patients
Although the link between HPR and ischemic event
occurrence is well established, the association between
on-treatment PR and bleeding events is less clear. Obser-
vational studies involving patients undergoing PCI have
suggested a possible link between LPR and bleeding
(Table 1) (8,9,11,13,18,58–63). A ﬁrst report suggested an
association between clopidogrel hyper-responsiveness (or
LPR) and post-discharge TIMI minor or major bleeding
events in a cohort of patients undergoing PCI for non–
ST-segment elevation MI (n ¼ 597). In this study, patients
in the ﬁrst quartile of 10 mmol/l ADP-induced platelet
aggregation (<40% aggregation) had more bleeding events
than patients in the other quartiles did (58). Following this
preliminary ﬁnding, further conﬁrmation came from a large
prospective cohort (n ¼ 2,533) in which a relationship
between post-PCI major non–coronary artery bypass graft
(CABG)–related bleeding and PR was observed (8).
The link between post-PCI non-CABG-related major
bleedings and LPR was also suggested by a retrospective
analysis of 346 patients using the VASP–platelet reactivity
index (PRI). In this study, lower PR measured by VASP-
PRI was observed in patients with non-CABG-related
TIMI major bleeding events, compared with patients
without major bleeding (32.5  22.4% vs. 51.2  21.9%;
p ¼ 0.006) (60). These ﬁndings regarding major bleedings
were reproduced in a prospective cohort of 310 patients
treated with clopidogrel, demonstrating a 4.5-fold increased
risk for TIMI major bleeding in patients in the lowest
quartile of VerifyNow PRU levels measured before PCI.Receiver-operating characteristic (ROC) curve analysis
identiﬁed the LPR cut point of PRU 189 to be the best
predictor of bleeding (61).
A link between PR and bleeding was further observed in
prasugrel-treated patients. Parodi et al. (63) reported that
patients undergoing PCI with LPR on prasugrel therapy
had more frequent access site bleeding. Accordingly, a
strong independent relationship between platelet inhibition
assessed by VASP-PRI and bleeding (including non-
CABG-related TIMI major or minor bleeding) during
1-year follow-up was reported in ACS patients treated with
prasugrel after successful PCI. Speciﬁcally, VASP-
PRI 16% was associated with a higher rate of bleeding
events. In multivariate analysis, VASP-PRI predicted both
thrombotic and bleeding events (odds ratio [OR]: 1.44, 95%
CI: 1.22 to 1.72; p < 0.001; and OR: 0.75, 95% CI: 0.59 to
0.96; p ¼ 0.024, respectively [per 10% increase]). The
frequency of thrombotic (excluding repeat revascularization)
and bleeding events at 1-year follow-up were similar in
this study (9). The observation of a link between non-
CABG-related major bleeding and LPR during prasugrel
therapy further supports the potential role of PFT, partic-
ularly as these ﬁndings do not appear to be speciﬁc for any
P2Y12 inhibitor. The consistent potent platelet inhibition
achieved in ticagrelor-treated patients with PR values pre-
senting within a small range have limited the ability to
determine a bleeding threshold in such patients, at least by
using the VerifyNow assay (64,65).
However, meaningful relationships between PR and
bleeding events were not observed in large-scale platelet
function studies such as the POPULAR (Do Platelet
Function Assays Predict Clinical Outcomes in Clopidogrel-
Pretreated Patients Undergoing Elective PCI), GRAVITAS,
and ARCTIC studies (11,13,18). A potential reason for the
discrepancy between the results of the latter trials and those
of smaller studies may be related to overall lower major
bleeding event rates, different bleeding deﬁnitions, and the
inclusion of procedural-related bleeding into the primary
endpoints. However, in the largest study of all, ADAPT-
DES (n ¼ 8,583), HPR (>208 PRU) was inversely
related to major bleeding (HR: 0.73, 95% CI: 0.61 to 0.89;
p ¼ 0.002) in a propensity-adjusted analysis accounting
for 84 baseline and treatment-related variables (16).
Relation of PR to Surgery-Related Bleeding
Some observational studies demonstrated a relation of
platelet function and bleeding in patients undergoing cardiac
surgery (Table 2) (66–69). The major rationale for 5-day
clopidogrel discontinuation recommended by the guide-
lines is the avoidance of excessive perioperative bleeding
by allowing recovery of platelet function (70). However,
demonstration of response variability, an w30% non-
responsiveness rate to clopidogrel therapy, and also vari-
ability in platelet function recovery following clopidogrel
therapy cessation indicate that an objective measurement of
Table 1 Relation Between Platelet-Function Measurement and Bleeding in Patients Treated With PCI
First Author/Study
(Ref. #) Patients (n); P2Y12 Treatment Platelet Function Test(s) Bleeding Criteria Outcome
Sibbing et al. (8) PCI (n ¼ 2,533); clopidogrel Multiplate analyzer,
ADP-induced aggregation
Procedure-related TIMI major
bleeding
<188 AU associated with 3.5
bleeding
Bonello et al. (9) ACS patients undergoing PCI
(n ¼ 301); prasugrel
VASP assay Major and minor TIMI bleeding VASP-PRI 16% associated with
major bleedings
GRAVITAS (11) PCI with DES implantation;
clopidogrel
VerifyNow P2Y12 assay GUSTO bleeding No association between bleeding
and platelet reactivity
ARCTIC (13) PCI (n ¼ 2,440); clopidogrel,
prasugrel
VerifyNow P2Y12 assay Major bleedingdSTEEPLE trial No association between
bleeding and platelet reactivity
POPULAR (18) PCI (n ¼ 1,069); clopidogrel LTA, VerifyNowP2Y12 assay;
Plateletworks;
IMPACT-R; PFA-100 with
collagen-ADP; Innovance
PFA P2Y
TIMI bleeding No relation between bleeding and
platelet reactivity measured
by any assay
Cuisset et al. (58) NSTE-ACS (n ¼ 597); clopidogrel LTA pre-heparin ADP-induced
aggregation and VASP-PRI
Non-CABG TIMI major and minor <40% aggregation associated with
higher risk of 30 days
post-discharge bleeding
Gurbel et al. (59) PCI (n ¼ 225); clopidogrel MA-ADP TEG platelet
mapping assay
31 MA-ADP associated with
post-PCI bleeding
Mokhtar et al. (60) PCI (n ¼ 346); clopidogrel VASP assay Non-CABG TIMI minor and major Low on-treatment PRI independent
predictor of bleedings
Patti et al. (61) PCI (n ¼ 310); clopidogrel VerifyNow P2Y12 assay TIMI major bleeding ROC analysis; 189 PRU associated
with bleeding
Tsukahara et al. (62) PCI (n ¼ 184); clopidogrel LTA REPLACE 2 bleeding First quartile of ADP-induced
aggregation associated with
bleeding
Parodi et al. (63) PCI (n ¼ 298); prasugrel LTA Entry site bleeding LPR associated with bleeding
ACS ¼ acute coronary syndromes; ADP ¼ adenosine diphosphate; ARCTIC ¼ Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-
Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting study; AU ¼ arbitrary aggregation unit(s); CABG ¼ coronary artery bypass graft; DES ¼ drug-eluting
stent(s); GRAVITAS ¼ Gauging Responsiveness With a VerifyNow AssaydImpact on Thrombosis and Safety; GUSTO ¼ Global Use of Strategies to Open Occluded Arteries; IMPACT-R ¼ cone and platelet
analyzer (IMPACT-R, Beersels, Belgium); LPR ¼ low platelet reactivity to adenosine diphosphate; LTA ¼ light transmittance aggregometry; MA ¼ maximum amplitude; NSTE-ACS, non–ST-segment elevation
acute coronary syndrome; PCI ¼ percutaneous coronary intervention; PFA ¼ platelet function analyzer; POPULAR ¼ Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated Patients
Undergoing Elective PCI study; PRI ¼ platelet reactivity index; PRU ¼ P2Y12 reaction units; REPLACE 2 ¼ Randomized Evaluations of PCI Linking Angiomax to Reduced Clinical Events trial; ROC ¼ receiver-
operating characteristic; STEEPLE ¼ Safety and Efﬁcacy of Enoxaparin in Percutaneous Coronary Intervention Patients, an International Randomized Evaluation trial; TEG ¼ thrombelastography; TIMI ¼
Thrombolysis In Myocardial Infarction; VASP ¼ vasodilator stimulated phosphoprotein-phosphorylation.
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2267the antiplatelet effect of clopidogrel before surgery may
obviate the need for the recommended standardized waiting
period in a substantial percentage of patients (71–73).
Chen et al. (66) demonstrated that <40% pre-heparin
ADP-induced aggregation predicted 92% of severe
bleeding needing multiple transfusions in patients on clo-
pidogrel undergoing ﬁrst-time on-pump CABG. Recently,Table 2 Relation Between Platelet Function Measurement and Bleed
First Author (Ref. #) Treatment Platelet Function Te
Chen et al. (66) Clopidogrel (n ¼ 45); on-pump CABG LTA (<40% pre-hepa
Mahla et al. (67) Clopidogrel or clopidogrel-naïve on
background aspirin (n ¼ 180);
on-pump CABG
MA-ADP TEG platele
Kwak et al. (68) Clopidogrel and aspirin (n ¼ 100);
off-pump CABG
MA-ADP TEG platele
(70% inhibition of
Ranucci et al. (69) Clopidogrel or ticlopidine (n ¼ 87);
CABG and/or valves
Multiplate analyzer
AUC ¼ area under the curve; CI ¼ conﬁdence interval; OR ¼ odds ratio; PA ¼ platelet aggregation; othethe prospective TARGET-CABG (Time Based Strategy
to Reduce Clopidogrel Associated Bleeding During CABG)
study demonstrated that stratifying clopidogrel-treated
patients on background aspirin therapy to speciﬁc waiting
periods based on a pre-operative assessment of clopidogrel
response resulted in similar perioperative bleeding, as
determined by chest tube output and transfusion of reding in Patients Undergoing Cardiac Surgery
st (Criteria for Bleeding) Outcome
rin ADP-induced PA) Low PA correlated with 92% of severe coagulopathies
that required multiple transfusions
t mapping assay Individualized pre-operative waiting in clopidogrel-
treated patients, as compared to clopidogrel-naïve
patients, resulted in similar bleeding and w50%
reduction of pre-operative waiting as compared to
that recommended in the guidelines
t mapping assay
PA)
Platelet inhibition >76% was the only independent
predictor of post-operative transfusion requirements
(OR: 11.44, 95% CI: 2.77–47.30; p ¼ 0.001)
ADP-induced platelet aggregation independently
predicted bleeding (cutoff: 31 U; AUC: 0.71;
p ¼ 0.013)
r abbreviations as in Table 1.
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2268blood cells, as compared to clopidogrel-naïve patients
undergoing elective ﬁrst-time on-pump CABG after
adjustment for potential confounders (67). In TARGET-
CABG, pre-operative clopidogrel response was measured
by thrombelastography with Platelet Mapping assay
(Haemonetics Corporation, Braintree, Massachusetts).
Surgery was scheduled with no delay in those patients with
an ADP-induced platelet-ﬁbrin clot strength (MAADP)
>50 mm, within 3 to 5 days in those with an MAADP ¼ 35
to 50 mm, and after 5 days in those with an MAADP
<35 mm (59). Compared with the guidelines, this indi-
vidualized approach reduced the pre-operative waiting
period by about 50% (68). Considering the preliminary
evidence from observational studies, the Society of Thoracic
Surgeons has given a Class IIa recommendation regarding
the use of PFT to assist in the timing of surgery (Online
Appendix, Box-2) (70).Therapeutic Window for P2Y12 Receptor Blockade
Early small turbidimetric aggregometry-based studies
demonstrated that ischemic event occurrences, including
periprocedural MI and ST, were not linearly related to on-
treatment PR but instead occurred above a moderate level
of on-treatment PR (74). Based on this preliminaryFigure 1 Evidence for P2Y12 Receptor Reactivity Associated With P
Similar to previously proposed high on-treatment platelet reactivity to ADP associated with
to ADP is associated with a higher risk of bleeding. Cutoff values for both ischemic and ble
both ischemic and bleeding events are inﬂuenced by various demographic variables. Ada
Alexander and Peterson (56), Gurbel et al. (59), and Campo et al. (76). ACS ¼ acute cor
DM ¼ diabetes mellitus; MA ¼ maximum amplitude; MEA ¼ multiplate analyzer; PRI ¼ p
thrombelastography; VASP ¼ vasodilator stimulated phosphoprotein-phosphorylation.evidence, it was ﬁrst hypothesized that a “therapeutic
window of PR” exists, similar to the international normal-
ized ratio range used for warfarin therapy (74).
In the ﬁrst observational study of 2,533 patients under-
going PCI, patients with >46 AU (arbitrary aggregation
units) were deﬁned as “clopidogrel low responders” based on
ROC curve analysis. This cut point was associated with the
primary efﬁcacy endpoint of 30-day incidence of deﬁnite or
probable ST. In contrast, patients with <19 AU were
deﬁned as “enhanced responders,” and this cut point was
associated with the primary safety endpoint of in-hospital
TIMI major bleeding (8). Subsequently, a MAADP >47
mm was shown to have a high predictive value for 3-year
post-PCI ischemic events during dual antiplatelet therapy.
Moreover, ROC curve and quartile analysis suggested
MAADP 31 mm as a predictive value for post-PCI
bleeding events (59). Similarly, a therapeutic window of 86
to 238 PRU was demonstrated by the VerifyNow testing in
another study of 300 patients undergoing PCI (73). In
a recent prospective study of 732 patients on dual anti-
platelet therapy, PR was measured before PCI using the
VerifyNow P2Y12 assay. Based on ROC curve analysis, an
LPR cutoff of 178 PRU was associated with 30-day
bleeding (area under the curve: 0.72; p < 0.0001) and an
HPR cutoff of 239 PRU was associated with ischemic
events (area under the curve: 0.68; p < 0.0001) (75).ost-PCI Ischemic and Bleeding Events
post-PCI ischemic events, recent data suggest that low on-treatment platelet reactivity
eding events based on various platelet function assays have been shown. In addition,
pted with permission from Sibbing et al. (8), Bonello et al. (9), Stone et al. (16),
onary syndromes; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft;
latelet reactivity index; PRU ¼ P2Y12 reaction units; ST ¼ stent thrombosis; TEG ¼
Figure 2 Therapeutic Window Concept for P2Y12 Receptor Reactivity
Evidence for high and low on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post–percutaneous coronary intervention (PCI) ischemic and bleeding
events based on (A) VerifyNow P2Y12 assay, (B) vasodilator stimulated phosphoprotein-phosphorylation assay, (C) Multiplate analyzer, and (D) thrombelastography platelet
mapping assay following P2Y12 receptor blocker therapy. Adapted with permission from Sibbing et al. (8), Bonello et al. (9), Gurbel et al. (59), and Campo et al. (76).
AU ¼ arbitrary aggregation units; other abbreviations as in Figure 1.
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>208 PRU was also inversely related to TIMI major
bleeding (adjusted HR: 0.73, 95% CI: 0.61 to 0.89;
p ¼ 0.002) (16). This observation is consistent with the
post-hoc analysis of the GRAVITAS trial, which found
that the achievement of a PRU <208 was associated
with signiﬁcantly improved clinical outcomes (36). Thus,Table 3
Platelet Reactivity Cutoff Associated With
Ischemic and Bleeding Events (Therapeutic Window)
Cutoff Associated
With Ischemic
Event Occurrences
(References)
Cutoff Associated
With Bleeding
Event Occurrences
(References)
VerifyNow PRU
assay, PRU
>208 (16,76) <85 (76)
Multiplate analyzer
ADP-induced
aggregation, AU
>46 (8) <19 (8)
Thrombelastography
platelet mapping
assay
ADP-induced
platelet-ﬁbrin
clot strength, mm
>47 (59) <31 (59)
VASP-PRI 50% (9) <16% (9)
Abbreviations as in Table 1.evidence for a therapeutic window of optimal on-treatment
PR to prevent both bleeding and ischemic events is
emerging. This window would therefore inform future
studies designed to optimally avoid thrombotic and bleeding
events during P2Y12 inhibitor therapy (8,9,16,56,59,76)
(Table 3, Figs. 1 and 2).Platelet Function Measurement
During New P2Y12 Inhibitor Therapy
In the platelet substudies of the TRITON–TIMI 38 (Trial
to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition With Prasugrel–Thrombol-
ysis In Myocardial Infarction 38) and PLATO (Platelet
Inhibition and Patient Outcomes) trials and pharmacody-
namic studies of ticagrelor and prasugrel in stable CAD
patients, it was observed that although the interindividual
variability in response to prasugrel and ticagrelor was
reduced, it was not absent (77–80). Recent studies demon-
strated that HPR is not limited to clopidogrel therapy but
also observed during treatment with the new and more
potent P2Y12 inhibitors. Moreover, the prognostic utility of
PFT may also be particularly important with respect to
bleeding during therapy with the new and potent P2Y12
inhibitors when LPR is more frequent than during
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prasugrel and clopidogrel therapy were similar. This obser-
vation is consistent with the fact that both are thienopyr-
idines; the mechanisms of action of their respective active
metabolites are the same; they share same receptor binding
site; and the active metabolites are pharmacodynamically
equipotent. The similar threshold to identify at-risk patients
treated with prasugrel or clopidogrel also indicates that on-
treatment reactivity, rather than the drug itself, is the
primary arbiter of outcome, further supporting the mecha-
nistic principle underlying PFT-guided antiplatelet therapy.
In a recent prospective study of ST-segment elevation
myocardial infarction patients undergoing PCI who were
randomized to ticagrelor or prasugrel therapy, although PR
did not differ between ticagrelor and prasugrel therapy, the
rates of HPR (>208 PRU) measured at 2 h after dosing
were 46.2% and 34.6%, respectively, and decreased signiﬁ-
cantly thereafter, not differing signiﬁcantly between the 2
agents through 5 days of measurement (6). In another
study, 50 patients with ST-segment elevation myocardial
infarction undergoing primary PCI on bivalirudin mono-
therapy were randomly treated with 60-mg prasugrel or
180-mg ticagrelor loading doses. The investigators demon-
strated that in only 50% of patients were both prasugrel and
ticagrelor therapies effective in inhibiting PR as measured
by VerifyNow assay, and at least 4 h were required to achieve
an effective platelet inhibition in the majority of patients
(10). These data suggest a delay in the pharmacodynamic
efﬁcacy of these drugs in selected ACS patients versus stable
patients. Thus far, there are no data available on the relation
between on-ticagrelor PR and bleeding/ischemic event
occurrence.
Conclusions and Recommendations
HPR can be considered a risk factor for post-PCI ST and
MI. The increased hazard associated with HPR has been
demonstrated with various PFT. The relation between
HPR and post-PCI ischemic event occurrence must be
considered in the context of the overall disease risk level
(i.e., ACS vs. non-ACS, diabetes vs. nondiabetes, old age,
and chronic kidney disease), post-PCI time (early [e.g.,
before 30 days] vs. late), and ethnicity. It appears that the
relation of PR to clinical outcome occurrence in the PCI
setting is stronger during the initial period (up to 30 to 60
days), when intensive P2Y12 inhibition may be more
effective. The relationship between PR and clinical
outcomes in medically-managed patients recovering from
ACS may be less robust.
The large randomized trials of personalized antiplatelet
therapy failed to conﬁrm the beneﬁt of PFT to improve
outcomes in patients at low absolute overall risk, resulting
in low post-discharge event rates and lack of power. These
randomized studies demonstrated that event rates are low
in low-risk patients undergoing PCI irrespective of PR,
and that high-dose clopidogrel is not an optimal strategyto overcome HPR and to improve clinical outcomes.
Strategies employing agents that are more potent have
largely remained untested in an adequate sample size of
patients. The evidence from the ARCTIC and GRAV-
ITAS trials have been used to support the hypothesis that
HPR is a nonmodiﬁable risk factor. An alternative expla-
nation is that the marker was not modiﬁed enough by high-
dose clopidogrel or that the absolute risk of the patient
population was not high enough, even though the patients
had HPR.
At present, PFT is helpful in identifying high-risk
patients, but its usefulness in inﬂuencing therapeutic
management deserves further evaluation in large-scale trials.
The overall low event rates observed in prospective trials
would require enrollment of a large number of patients to
deﬁnitively evaluate the utility of PFT for personalized
therapy in those patient populations. Unlike the selected
patients enrolled in prospective clinical studies, the risk of
clinical events may be higher in routine practice, and
personalized therapy may play a greater role.
An assessment of the utility of PFT in the individual
patient requires the synthesis of multiple factors. The
clinician should recognize the crucial role of platelet physi-
ology in catastrophic event occurrence such as ST and
should be cognizant of the guidelines. Furthermore, the
clinician should be aware of the existing observational data
demonstrating that HPR is a potent post-PCI risk factor
while keeping in mind the results of the 2 major randomized
trials, the populations studied, and the limitations of their
designs. At present, it appears that PFT may be most
appropriate in high-risk clopidogrel-treated patients with
current or prior ACS or a history of ST. In addition, patients
treated with clopidogrel who have poor left ventricular
function, complex anatomy, high body mass index, and
diabetes mellitus might be considered for PFT. PR should
not be regarded as the sole prognostic marker for thrombotic
event occurrence, but should rather be evaluated in relation
to patient risk. A risk algorithm that includes PFT along
with biomarker testing and clinical factors may improve
risk prediction and facilitate personalization of antiplatelet
therapy.
Emerging data suggest a relation of LPR to the risk of
bleeding. Unselected therapy with the new P2Y12 receptor
blockers is associated with increased bleeding. It is also
important to note that clopidogrel is pharmacodynamically
effective; its use results in an adequate P2Y12 receptor
inhibition, according to the above-proposed deﬁnition, in
about two-thirds of the patients undergoing PCI. Selectively
treating these patients with generic clopidogrel rather than
treating all patients with new and potent P2Y12 inhibitors
might provide signiﬁcant cost savings. Finally, personalized
antiplatelet therapy based on a concept of therapeutic win-
dow may improve the balance between better efﬁcacy and
reasonable safety. A trial to validate a therapeutic window
for P2Y12 inhibitors is warranted based on the information
presented in this consensus document.
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APPENDIX
For supplemental information regarding guidelines, please see the online
version of this article.
